SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2023.110997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Haoming Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC), one of the most common malignant tumors, is now afflicting approximately 80% of patients diagnosed with esophageal cancers. The therapeutic effect and prognosis of ESCC remain inadequate due to the unusual early symptoms and rapid malignant progression. SH2 Domain containing 4 A (SH2D4A) is downregulated in malignancies and is closely associated with tumor progression. However, neither the biological functions nor the fundamental mechanisms of SH2D4A on ESCC are known. In this study, it was found that SH2D4A is downregulated in ESCC tissues and cell lines. Incorporating immunohistochemistry and clinicopathological findings, we determined that decreased SH2D4A expression was substantially associated with adverse clinical outcomes. Overexpression of SH2D4A inhibited cell proliferation and migration, whereas suppressing SH2D4A has the opposite effect. SH2D4A mechanistically inhibited cells from proliferating and migrating through the FAK/PI3K/AKT signaling pathway. Furthermore, the results of xenograft tumor growth confirmed the preceding findings. In conclusion, our findings reveal that SH2D4A is a gene which can serve as a cancer suppressor in ESCC and may inhibits the ESCC progression by interfering with the FAK/PI3K/AKT signaling pathway. SH2D4A could act as a target for diagnostic or therapeutic purpose in ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.
- The First Branch, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.
- Department of Cell Biology and Medical Genetics, Molecular Medicine and Cancer Research Center, Chongqing Medical University, 400016 Chongqing, China.. Electronic address: duanchzhu@cqmu.edu.cn.
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.. Electronic address: wuqingchencqmu@126.com.
- Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.. Electronic address: shaoyuecq@163.com.
Zitieren
APA
Shi, H., Luo, J., Ye, L., Duan, C., Zhang, M., Ran, H., Li, C., Wu, Q., & Shao, Y. (2024). SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2023.110997
Vancouver
Shi H, Luo J, Ye L, Duan C, Zhang M, Ran H, et al. SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2023.110997
BibTeX
@article{Shi2024,
author = {Shi, Haoming and Luo, Jun and Ye, Liu and Duan, Changzhu and Zhang, Min and Ran, Haoyu and Li, Changying and Wu, Qingchen and Shao, Yue},
title = {SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2023.110997}
}
EUVIMED